Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K7 | O43318 | 17/20 | 0.53 |
| ▸ | TAB1 | Q15750 | 17/20 | 0.53 |
| ▸ | KDR | P35968 | 3/20 | 0.53 |
| ▸ | AURKB | Q96GD4 | 3/20 | 0.53 |
| ▸ | MET | P08581 | 3/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14693424 | 0.90 | MAP3K7 (0.52) | MAP3K7TAB1KDRAURKB | |
| SCHEMBL659703 | 0.90 | MAP3K7 (0.54) | MAP3K7TAB1KDRAURKB | |
| SCHEMBL659407 | 0.89 | MAP3K7 (0.47) | MAP3K7TAB1KDRAURKB | |
| SCHEMBL658706 | 0.87 | MAP3K7 (0.69) | MAP3K7TAB1KDRAURKB | |
| SCHEMBL660119 | 0.85 | MAP3K7 (0.64) | MAP3K7TAB1 | |
| SCHEMBL10217539 | 0.84 | MAP3K7 (0.50) | MAP3K7TAB1KDRAURKB | |
| SCHEMBL10218548 | 0.84 | MAP3K7 (0.76) | MAP3K7TAB1KDRAURKB | |
| SCHEMBL658942 | 0.83 | MAP3K7 (0.54) | MAP3K7TAB1KDRAURKB | |
| SCHEMBL10217545 | 0.82 | MAP3K7 (0.47) | MAP3K7TAB1KDRAURKB | |
| SCHEMBL658433 | 0.81 | MAP3K7 (0.46) | MAP3K7TAB1KDRAURKBMET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8378104-B2 | 7-aminofuropyridine derivatives | OSI Pharmaceuticals, LLC (US) | 2013-02-19 | — | — | US | disclosed |
| US-8378104-B2 | 7-aminofuropyridine derivatives | OSI Pharmaceuticals, LLC (US) | 2013-02-19 | — | — | US | disclosed |
| US-8378104-B2 | 7-aminofuropyridine derivatives | OSI Pharmaceuticals, LLC (US) | 2013-02-19 | — | — | US | disclosed |
| US-20120046267-A1 | 7-AMINOFUROPYRIDINE DERIVATIVES | OSI PHARMACEUTICALS, INC. | 2012-02-23 | — | — | US | disclosed |
| US-20120046267-A1 | 7-AMINOFUROPYRIDINE DERIVATIVES | OSI PHARMACEUTICALS, INC. | 2012-02-23 | — | — | US | disclosed |
| US-20120046267-A1 | 7-AMINOFUROPYRIDINE DERIVATIVES | OSI PHARMACEUTICALS, INC. | 2012-02-23 | — | — | US | disclosed |
| WO-2011100502-A1 | 7-AMINOFUROPYRIDINE DERIVATIVES | OSI Pharmaceuticals, LLC (US) | 2011-08-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120046267-A1 | 7-AMINOFUROPYRIDINE DERIVATIVES | MAP3K5, STK17A, MAPKAPK5 | MAP3K7 5/4885TAB1 4/4885KDR 3584/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.